Discussing Initiatives to Enable Better Alignment on the Use of Complex In Vitro Models with Regulatory Stakeholders
Time: 2:15 pm
day: Day 1
Details:
- Reintroducing the IQ-MPS affiliate and the goals of the regulatory working group to qualify CIVMs for regulatory use
- Discussing best practice when interacting with regulatory bodies like the FDA and global regulatory bodies
- Aligning on what CIVM data needs to be produced to instil confidence in the models externally
